Functional roles of osteoactivin in normal and disease processes

Critical Reviews in Eukaryotic Gene Expression

Volumn 20, Issue 4, 2010, Pages 341-357

  Singh, Maneet ^a   Del carpio Cano, Fabiola ^a   Belcher, Joyce Y ^a   Crawford, Kevin ^a   Frara, Nagat ^a   Owen, Thomas A ^b   Popoff, Steven N ^a   Safadi, Fayez F ^a,c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RAMAPO COLLEGE OF NEW JERSEY   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

Adhesion; Cancer; DC HIL; Glycoprotein nmb; HGFIN; Osteoactivin; Osteoblasts; Osteoclasts; PMEL17; Type I transmembrane glycoprotein

Indexed keywords

BREFELDIN A; DEXAMETHASONE; GLYCOPROTEIN; IMATINIB; MESSENGER RNA; OSTEOACTIVIN; UNCLASSIFIED DRUG; EYE PROTEIN; GPNMB PROTEIN, HUMAN; GPNMB PROTEIN, MOUSE; GPNMB PROTEIN, RAT; MEMBRANE PROTEIN;

ALBERS SCHOENBERG DISEASE; ARTICLE; BONE CELL; BONE DISEASE; HEPATITIS; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; MUSCLE ATROPHY; NEOPLASM; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PATHOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; SARCOLEMMA; SEQUENCE HOMOLOGY; TRANSCRIPTION REGULATION; ANIMAL; BONE; CHEMISTRY; GENETICS; LIVER; PATHOPHYSIOLOGY; REVIEW; SKELETAL MUSCLE; STRUCTURAL HOMOLOGY;

ANIMALS; BONE AND BONES; EYE PROTEINS; HUMANS; INFLAMMATION; LIVER; MEMBRANE GLYCOPROTEINS; MUSCLE, SKELETAL; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 79955027278     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukarGeneExpr.v20.i4.50     Document Type: Article

References (83)

1. Safadi FF, Xu J, Smock SL, Rico MC, Owen TA, Popof SN. Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts. J Cell Biochem. 2001;84(1):12-26.
2. Kuan CT, Wakiya K, Dowell JM, Herndon JE 2nd, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ, Bigner DD. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res. 2006;12(7 Pt 1):1970-82.
3. Pollack VA, Alvarez E, Tse KF, Torgov MY, Xie S, Shenoy SG, MacDougall JR, Arrol S, Zhong H, Gerwien RW, Hahne WF, Senter PD, Jefers ME, Lichenstein HS, LaRochelle WJ. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol. 2007;60(3):423-35.
4. Tse KF, Jefers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV, Hackett CS, Shenoy SG, Kuang B, Boldog FL, MacDougall JR, Rastelli L, Herrmann J, Gallo M, Gazit-Bornstein G, Senter PD, Meyer DL, Lichenstein HS, LaRochelle WJ. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res. 2006;12(4):1373-82.
5. Weterman MA, Ajubi N, van Dinter IM, Degen WG, van Muijen GN, Ruitter DJ, Bloemers HP. nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int J Cancer. 1995;60(1):73-81.
6. Okamoto I, Pirker C, Bilban M, Berger W, Losert D, Marosi C, Haas OA, Wolf K, Pehamberger H. Seven novel and stable translocations associated with oncogenic gene expression in malignant melanoma. Neoplasia. 2005;7(4):303-11.
7. Anderson MG, Libby RT, Mao M, Cosma IM, Wilson LA, Smith RS, John SW. Genetic context determines susceptibility to intraocular pressure elevation in a mouse pigmentary glaucoma. BMC Biol. 2006;4:20.
8. Anderson MG, Smith RS, Hawes NL, Zabaleta A, Chang B, Wiggs JL, John SW. Mutations in genes encoding mel-anosomal proteins cause pigmentary glaucoma in DBA/2J mice. Nat Genet. 2002;30(1):81-5.
9. Chung JS, Sato K, Dougherty II, Cruz PD Jr, Ariizumi K. DC-HIL is a negative regulator of T lymphocyte activation. Blood. 2007;109(10):4320-7.
10. Shikano S, Bonkobara M, Zukas PK, Ariizumi K. Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans. J Biol Chem. 2001;276(11):8125-34.
11. Chung JS, Dougherty I, Cruz PD Jr, Ariizumi K. Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation. J Immunol. 2007;179(9):5778-84.
12. Bandari PS, Qian J, Yehia G, Joshi DD, Maloof PB, Potian J, Oh HS, Gascon P, Harrison JS, Rameshwar P. Hematopoietic growth factor inducible neurokinin-1 type: a transmembrane protein that is similar to neurokinin 1 interacts with substance P. Regul Pept. 2003;111(1-3): 169-78.
13. Turque N, Denhez F, Martin P, Planque N, Bailly M, Bègue A, Stéhelin D, Saule S. Characterization of a new melanocyte-specifc gene (QNR-71) expressed in v-myc-transformed quail neuroretina. EMBO J. 1996;15(13): 3338-50.
14. Adema GJ, Bakker AB, de Boer AJ, Hohenstein P, Figdor CG. pMel17 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and HMB-50 and by anti-melanoma CTL. Br J Cancer. 1996;73(9):1044-8.
15. Bächner D, Schröder D, Gross G. mRNA expression of the murine glycoprotein (transmembrane) nmb (Gpnmb) gene is linked to the developing retinal pigment epithelium and iris. Brain Res Gene Expr Patterns. 2002;1(3-4): 159-65.
16. Owen TA, Smock SL, Prakash S, Pinder L, Brees D, Krull D, Castleberry TA, Clancy YC, Marks SC Jr, Safadi FF, Popof SN. Identifcation and characterization of the genes encoding human and mouse osteoactivin. Crit Rev Eukaryot Gene Expr. 2003;13(2-4):205-20.
17. Abdelmagid SM, Barbe MF, Rico MC, Salihoglu S, Arango-Hisijara I, Selim AH, Anderson MG, Owen TA, Popof SN, Safadi FF. Osteoactivin, an anabolic factor that regulates osteoblast diferentiation and function. Exp Cell Res. 2008;314(13):2334-51.
18. Schefers MS, Le H, van der Bent P, Leonhard W, Prins F, Spruit L, Breuning MH, de Heer E, Peters DJ. Distinct subcellular expression of endogenous polycystin-2 in the plasma membrane and Golgi apparatus of MDCK cells. Hum Mol Genet. 2002;11(1):59-67.
19. Hoashi T, Muller J, Vieira WD, Rouzaud F, Kikuchi K, Tamaki K, Hearing VJ. Te repeat domain of the mel-anosomal matrix protein PMEL17/GP100 is required for the formation of organellar fbers. J Biol Chem. 2006;281(30):21198-208.
20. Teos AC, Berson JF, Teos SC, Herman KE, Harper DC, Tenza D, Sviderskaya EV, Lamoreux ML, Bennett DC, Raposo G, Marks MS. Dual loss of ER export and endocytic signals with altered melanosome morphology in the silver mutation of Pmel17. Mol Biol Cell. 2006;17(8):3598-612.
21. Zerivitz K, Akusjärvi G. An improved nuclear extract preparation method. Gene Anal Tech. 1989;6(5):101-9.
22. Piccirillo R, Palmisano I, Innamorati G, Bagnato P, Altimare D, Schiafno MV. An unconventional dileucine-based motif and a novel cytosolic motif are required for the lysosomal and melanosomal targeting of OA1. J Cell Sci. 2006;119 (Pt 10):2003-14.
23. Setaluri V. Sorting and targeting of melanosomal membrane proteins: signals, pathways, and mechanisms. Pigment Cell Res. 2000;13(3):128-34.
24. Yasumoto K, Watabe H, Valencia JC, Kushimoto T, Kobayashi T, Appella E, Hearing VJ. Epitope mapping of the melanosomal matrix protein gp100 (PMEL17): rapid processing in the endoplasmic reticulum and gly-cosylation in the early Golgi compartment. J Biol Chem. 2004;279(27):28330-8.
25. Brunberg E, Andersson L, Cothran G, Sandberg K, Mikko S, Lindgren G. A missense mutation in PMEL17 is associated with the Silver coat color in the horse. BMC Genet. 2006;7:46.
26. Helip-Wooley A, Westbroek W, Dorward HM, Koshofer A, Huizing M, Boissy RE, Gahl WA. Improper traf-fcking of melanocyte-specifc proteins in Hermansky-Pudlak syndrome type-5. J Invest Dermatol. 2007;127(6): 1471-8.
27. Kemp EH, Waterman EA, Gawkrodger DJ, Watson PF, Weetman AP. Molecular mapping of epitopes on mel-anocyte-specifc protein Pmel17 which are recognized by autoantibodies in patients with vitiligo. Clin Exp Immunol. 2001;124(3):509-15.
28. Lally KM, Mocellin S, Ohnmacht GA, Nielsen MB, Bettinotti M, Panelli MC, Monsurro V, Marincola FM. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int J Cancer. 2001;93(6):841-7.
29. Nichols SE, Harper DC, Berson JF, Marks MS. A novel splice variant of Pmel17 expressed by human melanocytes and melanoma cells lacking some of the internal repeats. J Invest Dermatol. 2003;121(4):821-30.
30. Sensi M, Pellegatta S, Vegetti C, Nicolini G, Parmiani G, Anichini A. Identifcation of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones. Tissue Antigens. 2002;59(4):273-9.
31. Onaga M, Ido A, Hasuike S, Uto H, Moriuchi A, Nagata K, Hori T, Hayash K, Tsubouchi H. Osteoactivin expressed during cirrhosis development in rats fed a choline-defcient, L-amino acid-defned diet, accelerates motility of hepatoma cells. J Hepatol. 2003. 39(5):779-85.
32. Abe H, Uto H, Takami Y, Takahama Y, Hasuike S, Kodama M, Nagata K, Moriuchi A, Numata M, Ido A, Tsubouchi H. Transgenic expression of osteoactivin in the liver attenuates hepatic fbrosis in rats. Biochem Biophys Res Commun. 2007;356(3):610-5.
33. Ogawa T, Nikawa T, Furochi H, Kosyoji M, Hirasaka K, Suzue N, Sairyo K, Nakano S, Yamaoka T, Itakura M, Kishi K, Yasui N. Osteoactivin upregulates expression of MMP-3 and MMP-9 in fbroblasts infltrated into dener-vated skeletal muscle in mice. Am J Physiol Cell Physiol. 2005;289(3):C697-707.
34. Furochi H, Tamura S, Mameoka M, Yamada C, Ogawa T, Hirasaka K, Okumura Y, Imagawa T, Oguri S, Ishidoh K, Kishi K, Higashiyama S, Nikawa T. Osteoactivin fragments produced by ectodomain shedding induce MMP-3 expression via ERK pathway in mouse NIH-3T3 fbroblasts. FEBS Lett. 2007;581(30):5743-50.
35. Chung JS, Bonkobara M, Tomihari M, Cruz PD Jr, Ariizumi K. Te DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses. Eur J Immunol. 2009;39(4):965-74.
36. Hoashi T, Sato S, Yamaguchi Y, Passeron T, Tamaki K, Hearing VJ. Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specifc and proteolytically released protein. FASEB J. 2010;24(5): 1616-29.
37. Pahl MV, Vaziri ND, Yuan J, Adler SG. Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease. Clin J Am Soc Nephrol. 2010;5(1):56-61.
38. Ripoll VM, Meadows NA, Raggatt LJ, Chang MK, Pettit AR, Cassady AI, Hume DA. Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB. Gene. 2008;413(1-2):32-41.
39. Akiyama Y, Maruyama K, Watanabe M, Yamaguchi K. Retroviral-mediated IL-12 gene transduction into human CD34+ cell-derived dendritic cells. Int J Oncol. 2002; 21(3):509-14.
40. Selim AA, Castaneda JL, Owen TA, Popof SN, Safadi FF. Te role of osteoactivin-derived peptides in osteoblast diferentiation. Med Sci Monit. 2007;13(12):BR259-70.
41. Abdelmagid SM, Barbe MF, Arango-Hisijara I, Owen TA, Popof SN, Safadi FF. Osteoactivin acts as downstream mediator of BMP-2 efects on osteoblast function. J Cell Physiol. 2007;210(1):26-37.
42. Metz RL, Yehia G, Fernandes H, Donnelly RJ, Rameshwar P. Cloning and characterization of the 5' fanking region of the HGFIN gene indicate a cooperative role among p53 and cytokine-mediated transcription factors: relevance to cell cycle regulation. Cell Cycle. 2005;4(2):315-22.
43. Selim AA, Abdelmagid SM, Kanaan RA, Smock SL, Owen TA, Popof SN, Safadi FF. Anti-osteoactivin antibody inhibits osteoblast diferentiation and function in vitro. Crit Rev Eukaryot Gene Expr. 2003;13(2-4):265-75.
44. Abdelmagid SM, Barbe MF, Hadjiargyrou M, Owen TA, Razmpour R, Rehman S, Popof SN, Safadi FF. Temporal and spatial expression of osteoactivin during fracture repair. J Cell Biochem. 2010;111(2):295-309.
45. Sheng MH, Wergedal JE, Mohan S, Lau KH. Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast diferentiation and activity. FEBS Lett. 2008;582(10):1451-8.
46. Tomihari M, Hwang SH, Chung JS, Cruz PD Jr, Ariizumi K. Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD-dependent fashion. Exp Dermatol. 2009;18(7):586-95.
47. Karlsson C, Dehne T, Lindahl A, Brittberg M, Pruss A, Sittinger M, Ringe J. Genome-wide expression profling reveals new candidate genes associated with osteoarthritis. Osteoarthritis Cartilage. 2010;18(4):581-92.
48. Rose AA, Annis MG, Dong Z, Pepin F, Hallett M, Park M, Siegel PM. ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angio-genic properties. PLoS One. 2010;5(8):e12093.
49. Rose AA, Grosset AA, Dong Z, Russo C, Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park M, Gaboury L, Siegel PM. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res. 2010;16(7):2147-56.
50. Rose AA, Pepin F, Russo C, Abou Khalil JE, Hallett M, Siegel PM. Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res. 2007;5(10):1001-14.
51. Rose AA, Siegel PM.Osteoactivin/HGFIN: is it a tumor suppressor or mediator of metastasis in breast cancer? Breast Cancer Res. 2007;9(6):403.
52. Rose AA, Siegel PM. Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol. 2010;6(1):55-74.
53. Haraszti T, Trantow CM, Hedberg-Buenz A, Grunze M, Anderson MG. Spectral analysis by XANES reveals that GPNMB influences the chemical composition of intact melanosomes. Pigment Cell Melanoma Res. 2011;24(1):187-96.
54. Reiter F, Hartl M, Karagiannidis AI, Bister K. WS5, a direct target of oncogenic transcription factor Myc, is related to human melanoma glycoprotein genes and has oncogenic potential. Oncogene. 2007;26(12):1769-79.
55. Rich JN, Shi Q, Hjelmeland M, Cummings TJ, Kuan CT, Bigner DD, Counter CM, Wang XF. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defned human cancer model. J Biol Chem. 2003;278(18):15951-7.
56. Ripoll VM, Irvine KM, Ravasi T, Sweet MJ, Hume DA. Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinfammatory responses. J Immunol. 2007;178(10): 6557-66.
57. Haralanova-Ilieva B, Ramadori G, Armbrust T. Expression of osteoactivin in rat and human liver and isolated rat liver cells. J Hepatol. 2005;42(4):565-72.
58. Selim AA. Osteoactivin bioinformatic analysis: prediction of novel functions, structural features, and modes of action. Med Sci Monit. 2009;15(2):MT19-33.
59. Berson JF, Harper DC, Tenza D, Raposo G, Marks MS. Pmel17 initiates premelanosome morphogenesis within mul-tivesicular bodies. Mol Biol Cell. 2001;12(11):3451-64.
60. Hoashi T, Sato S, Yamaguchi Y, Passeron T, Tamaki K, Hearing VJ. Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specifc and proteolytically released protein. FASEB J. 2010;24(5): 1616-29.
61. Howell GR, Libby RT, Marchant JK, Wilson LA, Cosma IM, Smith RS, Anderson MG, John SW.Absence of glaucoma in DBA/2J mice homozygous for wild-type versions of Gpnmb and Tyrp1. BMC Genet. 2007;8:45.
62. Harper DC, Teos AC, Herman KE, Tenza D, Raposo G, Marks MS. Premelanosome amyloid-like fbrils are composed of only golgi-processed forms of Pmel17 that have been proteolytically processed in endosomes. J Biol Chem. 2008;283(4):2307-22.
63. Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. Te response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005;102(44):16013-8.
64. Mo JS, Anderson MG, Gregory M, Smith RS, Savinova OV, Serreze DV, Ksander BR, Streilein JW, John SW. By altering ocular immune privilege, bone marrow-derived cells pathogenically contribute to DBA/2J pigmentary glaucoma. J Exp Med. 2003;197(10):1335-44.
65. Ahn JH, Lee Y, Jeon C, Lee SJ, Lee BH, Choi KD, Bae YS. Identifcation of the genes diferentially expressed in human dendritic cell subsets by cDNA subtraction and microarray analysis. Blood. 2002;100(5):1742-54.
66. Nakamura A, Ishii A, Ohata C, Komurasaki T. Early induction of osteoactivin expression in rat renal tubular epithelial cells after unilateral ureteral obstruction. Exp Toxicol Pathol. 2007.
67. Furochi H, Tamura S, Takeshima K, Hirasaka K, Nakao R, Kishi K, Nikawa T. Overexpression of osteoactivin protects skeletal muscle from severe degeneration caused by long-term denervation in mice. J Med Invest. 2007;54(3-4): 248-54.
68. Akiyoshi H, Chung JS, Tomihari M, Cruz PD Jr, Ariizumi K. Depleting syndecan-4+ T lymphocytes using toxin-bearing dendritic cell-associated heparan sulfate proteoglycan-dependent integrin ligand: a new opportunity for treating activated T cell-driven disease. J Immunol. 2010;184(7):3554-61.
69. Tomihari M, Chung JS, Akiyoshi H, Cruz PD Jr, Ariizumi K. DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells. Cancer Res. 2010;70(14):5778-87.
70. Buck CA, Horwitz AF.Cell surface receptors for extracellular matrix molecules. Annu Rev Cell Biol. 1987;3:179-205.
71. Rahman S, Aitken A, Flynn G, Formstone C, Savidge GF. Modulation of RGD sequence motifs regulates dis-integrin recognition of alphaIIb beta3 and alpha5 beta1 integrin complexes. Replacement of elegantin alanine-50 with proline, N-terminal to the RGD sequence, diminishes recognition of the alpha5 beta1 complex with restoration induced by Mn2+ cation. Biochem J. 1998;335(Pt 2):247-57.
72. Li Q, Smith AJ, Schacker TW, Carlis JV, Duan L, Reilly CS, Haase AT. Microarray analysis of lymphatic tissue reveals stage-specifc, gene expression signatures in HIV-1 infection. J Immunol. 2009;183(3):1975-82.
73. Ghilardi C, Chiorino G, Dossi R, Nagy Z, Giavazzi R, Bani M. Identifcation of novel vascular markers through gene expression profling of tumor-derived endothelium. BMC Genomics. 2008;9:201.
74. Mokarram P, Kumar K, Brim H, Naghibalhossaini F, Saberi-froozi M, Nouraie M, Green R, Lee E, Smoot DT, Ashktorab H. Distinct high-profle methylated genes in colorectal cancer. PLoS One. 2009;4(9):e7012.
75. Orlichenko LS, Radisky DC. Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis. 2008;25(6):593-600.
76. Mendes O, Kim HT, Stoica G. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis. 2005;22(3):237-46.
77. Metz RL, Patel PS, Hameed M, Bryan M, Rameshwar P. Role of human HGFIN/nmb in breast cancer. Breast Cancer Res. 2007;9(5):R58.
78. Qian X, Mills E, Torgov M, LaRochelle WJ, Jefers M. Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate. Mol Oncol. 2008;2(1):81-93.
79. Anderson MG, Smith RS, Savinova OV, Hawes NL, Chang B, Zabaleta A, Wilpan R, Heckenlively JR, Davisson M, John SW. Genetic modifcation of glaucoma associated phenotypes between AKXD-28/Ty and DBA/2J mice. BMC Genet. 2001;2:1.
80. Ott C, Iwanciw D, Graness A, Giehl K, Goppelt-Struebe M. Modulation of the expression of connective tissue growth factor by alterations of the cytoskeleton. J Biol Chem. 2003;278(45):44305-11.
81. Loftus SK, Antonellis A, Matera I, Renaud G, Baxter LL, Reid D, Wolfsberg TG, Chen Y, Wang C; NISC Comparative Sequencing Program, Prasad MK, Bessling SL, McCallion AS, Green ED, Bennett DC, Pavan WJ. Gpnmb is a melanoblast-expressed, MITF-dependent gene. Pigment Cell Melanoma Res. 2009;22(1):99-110.
82. Schneider GB, Zaharias R, Stanford C. Osteoblast integrin adhesion and signaling regulate mineralization. J Dent Res. 2001;80(6):1540-4.
83. Lai CF, Cheng SL. Alphavbeta integrins play an essential role in BMP-2 induction of osteoblast diferentiation. J Bone Miner Res. 2005;20(2):330-40.